ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2019, 'Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer', Annals of Oncology, 30, pp. 1472 - 1478, http://dx.doi.org/10.1093/annonc/mdz200
,2019, 'The Upper Gastrointestinal Cancer Registry (UGICR): A clinical quality registry to monitor and improve care in upper gastrointestinal cancers', BMJ Open, 9, pp. e031434, http://dx.doi.org/10.1136/bmjopen-2019-031434
,2019, 'Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test', Journal of Cancer Survivorship, 13, pp. 495 - 502, http://dx.doi.org/10.1007/s11764-019-00769-7
,2019, 'Patient perspectives on molecular tumor profiling: "why wouldn't you?"', BMC Cancer, 19, pp. 753, http://dx.doi.org/10.1186/s12885-019-5920-x
,2019, 'An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes', Annals of oncology : official journal of the European Society for Medical Oncology, 30, pp. iv126, http://dx.doi.org/10.1093/annonc/mdz154
,2019, 'Analysis of patient screening in the phase III, international, randomized, open-label APACT trial', Annals of oncology : official journal of the European Society for Medical Oncology, 30, pp. iv110, http://dx.doi.org/10.1093/annonc/mdz156
,2019, 'APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.', Journal of Clinical Oncology, 37, pp. 4000 - 4000, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.4000
,2019, 'Medical oncologists’ experience with returning molecular tumor profiling to patients.', Journal of Clinical Oncology, 37, pp. 10521 - 10521, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.10521
,2019, 'NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.', Journal of Clinical Oncology, 37, pp. TPS4156 - TPS4156, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.tps4156
,2019, 'Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.TPS3622
,2019, 'Challenges and perceived unmet needs of Chinese migrants affected by cancer: Focus group findings', Journal of Psychosocial Oncology, 37, pp. 383 - 397, http://dx.doi.org/10.1080/07347332.2018.1551261
,2019, 'Evaluation of an online communication skills training programme for oncology nurses working with patients from minority backgrounds', Supportive Care in Cancer, 27, pp. 1951 - 1960, http://dx.doi.org/10.1007/s00520-018-4507-4
,2019, 'CanStem111P trial: A Phase III study of napabucasin plus nab-paclitaxel with gemcitabine', Future Oncology, 15, pp. 1295 - 1302, http://dx.doi.org/10.2217/fon-2018-0903
,2019, 'Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus', HPB, 21, pp. 444 - 455, http://dx.doi.org/10.1016/j.hpb.2018.08.016
,2019, 'Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review', Journal of Surgical Oncology, 119, pp. 489 - 496, http://dx.doi.org/10.1002/jso.25320
,2019, 'The Impact of Positive Resection Margins on Survival and Recurrence following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma', Annals of Surgery, 269, pp. 520 - 529, http://dx.doi.org/10.1097/SLA.0000000000002557
,2019, 'Dorsal root ganglion explants derived from chemotherapy-treated mice have reduced neurite outgrowth in culture', Neuroscience Letters, 694, pp. 14 - 19, http://dx.doi.org/10.1016/j.neulet.2018.11.016
,2019, 'Balance deficits and functional disability in cancer survivors exposed to neurotoxic cancer treatments', JNCCN Journal of the National Comprehensive Cancer Network, 17, pp. 949 - 955, http://dx.doi.org/10.6004/jnccn.2019.7290
,2019, 'Salvage laryngectomy and laryngopharyngectomy: Multicenter review of outcomes associated with a reconstructive approach', Head and Neck, 41, pp. 16 - 29, http://dx.doi.org/10.1002/hed.25192
,2019, 'Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses', Annals of Oncology, 30, pp. v259 - v260, http://dx.doi.org/10.1093/annonc/mdz247.010
,2019, 'Randomised Phase 3 Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) - INTEGRATE II', Annals of Oncology, 30, pp. vi137 - vi137, http://dx.doi.org/10.1093/annonc/mdz343.087
,2018, 'Evaluation of an online communication skills training programme for oncology nurses working with patients from minority backgrounds', Supportive Care in Cancer, http://dx.doi.org/10.1007/s00520-018-4507-4
,2018, 'Association between pancreatic cancer patients' perception of their care coordination and patient-reported and survival outcomes', Palliative and Supportive Care, 16, pp. 534 - 543, http://dx.doi.org/10.1017/S1478951517000608
,2018, 'Predictors of care for patients with cancer of unknown primary site in three Australian hospitals', Asia-Pacific Journal of Clinical Oncology, 14, pp. e512 - e520, http://dx.doi.org/10.1111/ajco.12815
,2018, 'Radiotherapy for anal squamous cell carcinoma: must the upper pelvic nodes and the inguinal nodes be treated?', ANZ Journal of Surgery, 88, pp. 870 - 875, http://dx.doi.org/10.1111/ans.14398
,2018, 'Chemotherapy in patients with unresected pancreatic cancer in Australia: A population-based study of uptake and survival', Asia-Pacific Journal of Clinical Oncology, 14, pp. 326 - 336, http://dx.doi.org/10.1111/ajco.12862
,2018, 'Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial', The Lancet, 392, pp. 123 - 133, http://dx.doi.org/10.1016/S0140-6736(18)31257-1
,2018, 'A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy', Contemporary Clinical Trials, 70, pp. 135 - 138, http://dx.doi.org/10.1016/j.cct.2018.04.011
,2018, 'Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines', International Journal of Oncology, 52, pp. 2143 - 2154, http://dx.doi.org/10.3892/ijo.2018.4337
,2018, 'CanStem111P trial: A Phase 3 Study of napabucasin (NAPA) plus nab-paclitaxel (nPTX) with gemcitabine (Gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC) - Trial in progress', Annals of oncology : official journal of the European Society for Medical Oncology, 29, pp. v51 - v52, http://dx.doi.org/10.1093/annonc/mdy151.183
,2018, 'Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer', Cancer Management and Research, 10, pp. 1389 - 1396, http://dx.doi.org/10.2147/CMAR.S163475
,2018, 'Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.', JOURNAL OF CLINICAL ONCOLOGY, 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.e16206
,2018, 'Patients’ preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile?', Journal of Clinical Oncology, 36, pp. 3602 - 3602, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.3602
,2018, 'Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma', Gastric Cancer, 21, pp. 473 - 480, http://dx.doi.org/10.1007/s10120-017-0754-1
,2018, 'The PiGeOn project: Protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer', BMC Cancer, 18, pp. 389, http://dx.doi.org/10.1186/s12885-018-4366-x
,2018, 'Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer', British Journal of Cancer, 118, pp. 947 - 954, http://dx.doi.org/10.1038/s41416-018-0004-2
,2018, 'Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy', British Journal of Cancer, 118, pp. 1084 - 1088, http://dx.doi.org/10.1038/s41416-018-0005-1
,2018, 'Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy', Muscle and Nerve, 57, pp. 615 - 621, http://dx.doi.org/10.1002/mus.25968
,2018, 'Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice', Muscle and Nerve, 57, pp. 650 - 658, http://dx.doi.org/10.1002/mus.25966
,2018, 'Barriers and facilitators of exercise experienced by cancer survivors: a mixed methods systematic review', Supportive Care in Cancer, 26, pp. 685 - 700, http://dx.doi.org/10.1007/s00520-017-3964-5
,2018, 'Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease', The Lancet Oncology, 19, pp. e151 - e160, http://dx.doi.org/10.1016/S1470-2045(18)30098-6
,2018, 'Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: A prospective biomarker study', Gut, 68, pp. 663 - 671, http://dx.doi.org/10.1136/gutjnl-2017-315852
,2018, 'Biliary Stenting in Patients with Pancreatic Cancer: Results from a Population-Based Cohort Study', Pancreas, 47, pp. 80 - 86, http://dx.doi.org/10.1097/MPA.0000000000000960
,2018, '5. Neurophysiological dysfunction in chemotherapy-treated patients: Comparison of different platinum analogues', Clinical Neurophysiology, 129, pp. e2 - e3, http://dx.doi.org/10.1016/j.clinph.2017.12.018
,2018, '517 - World-First Identification of Circulating Pancreatic Stellate Cells in Metastatic Pancreatic Cancer', Gastroenterology, 154, pp. S - 114, http://dx.doi.org/10.1016/s0016-5085(18)30816-3
,2018, 'Targeting a solute carrier to metabolically reprogram tumour-promoting stromal cells in pancreatic cancer', Pancreatology, 18, pp. S156 - S156, http://dx.doi.org/10.1016/j.pan.2018.05.419
,2017, 'Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey', Supportive Care in Cancer, 25, pp. 3485 - 3493, http://dx.doi.org/10.1007/s00520-017-3772-y
,2017, 'Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty', Expert Review of Anticancer Therapy, 17, pp. 951 - 964, http://dx.doi.org/10.1080/14737140.2017.1369882
,2017, 'Communication challenges experienced by migrants with cancer: A comparison of migrant and English-speaking Australian-born cancer patients', Health Expectations, 20, pp. 886 - 895, http://dx.doi.org/10.1111/hex.12529
,2017, 'Information needs of the Chinese community affected by cancer: A systematic review', Psycho-Oncology, 26, pp. 1433 - 1443, http://dx.doi.org/10.1002/pon.4347
,